Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

We recently published 10 Stocks That Jim Cramer Talked About. CVS Health Corporation (NYSE:CVS) is one of the stocks Jim ...

Eli Lilly › Great businesses have a habit of remaining so even when market volatility arises. The stock market is cyclical, ...

While competitors continue to struggle with healthcare costs, Aetna and CVS are celebrating an 8.4% increase in ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than ...

CVS Health raised its full-year profit forecast after exceeding Wall Street quarterly earnings estimates on Thursday, as ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...